Losing weight can be a challenging journey, but advancements in medical science have introduced a revolutionary new category of treatments: incretin-mimicking hormones. These powerful medications, originally developed to manage type 2 diabetes, have also demonstrated remarkable weight loss benefits.
In this blog post, we’ll explore what incretin hormones are, how their mimicking medications work, and a comprehensive overview of all the options on the market — including some exciting therapies still pending FDA approval for weight loss.
Understanding Incretins: GLP-1, GIP, and Amylin
ncretins are naturally occurring hormones that play a critical role in metabolism:
- GLP-1 (Glucagon-like peptide-1): Promotes insulin secretion, suppresses appetite, slows gastric emptying, and helps regulate blood sugar.
- GIP (Glucose-dependent insulinotropic polypeptide): Stimulates insulin after meals and may enhance fat metabolism.
- Amylin (not an incretin but often discussed alongside): Works with insulin to regulate blood glucose and promotes satiety by slowing gastric emptying.
Medications that mimic these hormones activate specific receptors in the brain and gut, leading to appetite suppression, better glucose control, and substantial weight loss.
A Fascinating Discovery: From Gila Monster to Medical Marvel
The origins of incretin-based therapy are as fascinating as the results they deliver today.
In the 1990s, scientists discovered that the saliva of the Gila monster, a slow-moving desert lizard, contained a hormone called exendin-4.
Exendin-4 acts similarly to GLP-1 in the human body — regulating blood sugar, promoting insulin secretion, and reducing appetite. Remarkably, this natural molecule resisted rapid breakdown, giving it a longer-lasting effect compared to human GLP-1.
Building on this discovery, researchers developed exenatide (Byetta), the first GLP-1 receptor agonist, which was approved by the FDA in 2005 for type 2 diabetes.
Since then, medical science has rapidly evolved:
- Newer GLP-1 drugs like liraglutide (approved in 2010) and semaglutide (approved in 2017 for diabetes and in 2021 as Wegovy for weight loss) offer longer action and even greater weight loss.
- The field expanded further with dual agonists like tirzepatide and emerging triple agonists under investigation today.
From a lizard’s survival mechanism to life-changing weight loss therapies — it’s a testament to the incredible power of scientific discovery and innovation.
GLP-1 Receptor Agonists
These are the original incretin mimickers, and they remain highly effective for weight loss:
| Medication | Brand Name | FDA-Approved for Weight Loss? | Notes |
| Semaglutide | Wegovy (for weight loss), Ozempic (for diabetes) | Yes (Wegovy) | Among the most powerful weight loss medications available, with ~15% body weight reduction seen in trials. |
| Liraglutide | Saxenda (for weight loss), Victoza (for diabetes) | Yes (Saxenda) | Older generation, still effective (~5-10% weight loss), daily injection. |
| Exenatide | Byetta, Bydureon | No | Approved for diabetes; modest weight loss. |
| Dulaglutide | Trulicity | No | Primarily for diabetes, some weight loss observed. |
| Lixisenatide | Adlyxin | No | Minimal weight loss effect, mainly diabetes control. |
Mechanism: These medications stimulate GLP-1 receptors to reduce appetite, slow digestion, and stabilize blood sugar levels.
Dual Agonists: GLP-1 + GIP Receptor Agonists
This exciting newer class combines GLP-1 and GIP effects for even more powerful outcomes:
| Medication | Brand Name | FDA-Approved for Weight Loss? | Notes |
| Tirzepatide | Mounjaro (for diabetes), Zepbound (for weight loss) | Yes (Zepbound) | Tremendous results: ~20% body weight reduction reported in clinical trials. |
Mechanism: Tirzepatide acts on both GLP-1 and GIP receptors, leading to stronger appetite suppression and enhanced fat metabolism compared to GLP-1 alone.
Emerging Triple Agonists: GLP-1 + GIP + Glucagon
Still under clinical investigation, triple agonists show even more promise:
| Medication | Brand Name | FDA-Approved for Weight Loss? | Notes |
| Retatrutide | (No brand name yet) | No (in clinical trials) | Preliminary data suggests up to 24% body weight reduction — an unprecedented result. |
Mechanism: Triple agonists activate GLP-1, GIP, and glucagon receptors, potentially boosting energy expenditure and enhancing fat loss while maintaining glucose control.
Additional Related Therapies: Amylin Analogs
Though not true incretins, amylin mimetics work synergistically with incretin therapy:
| Medication | Brand Name | FDA-Approved for Weight Loss? | Notes |
| Cagrilintide | (in trials, often combined with semaglutide) | No | High potential in combination with GLP-1 agents for even greater satiety and weight loss. |
| Pramlintide | Symlin | No | Approved for diabetes; promotes fullness, modest weight loss |
Why These Medications Work So Well
Incretin mimicking medications don’t just curb hunger — they fundamentally reprogram your body’s metabolic setpoint by:
- Enhancing insulin sensitivity
- Decreasing cravings and compulsive eating
- Reducing inflammation
- Shifting body composition away from visceral fat accumulation
At Storm Wellness Northwest, we focus on personalized, medically-supervised weight management programs that incorporate these cutting-edge treatments alongside holistic lifestyle coaching.
Side Effects and Considerations
As with any powerful therapy, incretin mimickers come with potential side effects, most commonly:
- Nausea, vomiting, diarrhea
- Constipation
- Risk of pancreatitis (rare)
- Gallbladder concerns (rare)
Good news: Most gastrointestinal symptoms are temporary and can be minimized through slow dose escalation, diet adjustments, and expert guidance — something we specialize in.
Are You Ready for Your Transformation?
If you’re curious about whether GLP-1, GIP, dual, or even triple agonist therapy could be right for you, we would love to help you navigate your options.
➡️ Make your “Initial Weight Loss” appointment today by following this link!
You’ll meet with our experienced nurse practitioner for a personalized 45-minute consultation to discuss your health goals, medication options, and craft a plan that supports lasting success.
References
- Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385, 503-515. doi:10.1056/NEJMoa2107519
- Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. doi:10.1056/NEJMoa2032183
- Bettge, K., et al. (2017). Body weight effects of GLP-1 receptor agonists: a meta-analysis of randomized controlled trials. Obesity Reviews, 18(8), 692-708. doi:10.1111/obr.12528
- Rosenstock, J., et al. (2024). Retatrutide, a Triple Hormone Receptor Agonist, in Obesity. New England Journal of Medicine, 390, 1020-1031. doi:10.1056/NEJMoa2300213
